Hologic, Inc. Stock

Equities

HOLX

US4364401012

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-05-14 pm EDT 5-day change 1st Jan Change
75.65 USD +0.11% Intraday chart for Hologic, Inc. -0.59% +5.88%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 4.03B Sales 2025 * 4.25B Capitalization 17.64B
Net income 2024 * 805M Net income 2025 * 866M EV / Sales 2024 * 4.43 x
Net Debt 2024 * 216M Net cash position 2025 * 863M EV / Sales 2025 * 3.95 x
P/E ratio 2024 *
22.4 x
P/E ratio 2025 *
20.5 x
Employees 6,990
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.02%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.11%
1 week-0.59%
Current month-0.16%
1 month-2.17%
3 months+3.42%
6 months+5.16%
Current year+5.88%
More quotes
1 week
74.64
Extreme 74.6401
76.43
1 month
74.53
Extreme 74.53
79.75
Current year
70.53
Extreme 70.53
79.75
1 year
64.02
Extreme 64.02
82.45
3 years
59.78
Extreme 59.78
87.88
5 years
26.49
Extreme 26.49
87.88
10 years
22.70
Extreme 22.7
87.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 13-12-06
Director of Finance/CFO 54 05-12-31
Chief Operating Officer 44 17-08-31
Members of the board TitleAgeSince
Chief Executive Officer 60 13-12-06
Director/Board Member 69 17-05-14
Director/Board Member 63 16-11-30
More insiders
Date Price Change Volume
24-05-14 75.65 +0.11% 1,268,454
24-05-13 75.57 +0.57% 1,039,454
24-05-10 75.14 -0.81% 1,402,648
24-05-09 75.75 -0.15% 2,037,848
24-05-08 75.86 -0.32% 973,729

Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT

More quotes
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
75.57 USD
Average target price
85 USD
Spread / Average Target
+12.48%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW